| 2.415 -0.435 (-15.26%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.52  |
1-year : | 5.27 |
| Resists | First : | 3.86 |
Second : | 4.52 |
| Pivot price | 0.96 |
|||
| Supports | First : | 1.75 |
Second : | 0.44 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 0.84 |
| MA(100) : | 0.59 |
MA(250) : | 1.13 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 72.3 |
D(3) : | 67.3 |
| RSI | RSI(14): 80.2 |
|||
| 52-week | High : | 3.86 | Low : | 0.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RANI ] has closed below upper band by 6.3%. Bollinger Bands are 1232.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.87 - 3.89 | 3.89 - 3.91 |
| Low: | 2.23 - 2.24 | 2.24 - 2.25 |
| Close: | 2.39 - 2.42 | 2.42 - 2.43 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Wed, 22 Oct 2025
Pre Market Movers: RANI, ISRG, ALEC In The Spotlight - RTTNews
Tue, 21 Oct 2025
How to manage a losing position in Rani Therapeutics Holdings Inc. - 2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Mon, 20 Oct 2025
Maxim Group Maintains Rani Therapeutics Holdings (RANI) Buy Recommendation - Nasdaq
Mon, 20 Oct 2025
Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai (RANI) - Seeking Alpha
Sun, 19 Oct 2025
Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost - Yahoo Finance
Fri, 17 Oct 2025
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.362e+007 (%) |
| Held by Institutions | 19.5 (%) |
| Shares Short | 103 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.455e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 796.7 % |
| Return on Equity (ttm) | -94 % |
| Qtrly Rev. Growth | 1.2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1564.41 |
| EBITDA (p.s.) | 4.12e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.17 |
| Dividend | 0 |
| Forward Dividend | 149330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|